Camidanlumab Tesirine
ADC Therapeutics
['lymsm', 'lymphoma']
#eha2022 | , discussed phase ii results for camidanlumab tesirine, an antibody-drug conjugate, in pts with r/r chl. -&gt; cami demonstrated an orr of 70.1% (cr: 33.3%), median dor of 13.7 mos and median pfs of 9.1 mo #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm